Corline Biomedical AB

CLBIO · Nasdaq Stockholm · Healthcare

15.20SEK +5.9%last day

Price as of 2 October 2026

The price over the past year, with dividends: −23.2%

Performance

1 month

−5.9%

1 year

−23.2%

3 years, per year

−0.6%

5 years, per year

−2.0%

Largest fall, 3 years

−65.9%

Below the peak now

−44.6%

Volatility, 1 year

44.6%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

3.9

Dividend yield

0.0%

Return on equity

−12.4%

Net margin

−99.5%

Market value

40 m USD

Quality, value and trend

Where Corline Biomedical stands against every Nordic stock today. 100 is best.

Quality29

Profitability and a sound balance sheet over time. Better than 29% of Nordic stocks.

Value9

The price measured against earnings, assets and cash flow. Better than 9% of Nordic stocks.

Trend22

The price development over the past year. Better than 22% of Nordic stocks.

Combined5

Quality, value and trend together. Better than 5% of Nordic stocks.

About Corline Biomedical

Corline Biomedical AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 14 employees.

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis